Clinical

Dataset Information

0

MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer


ABSTRACT: This phase I trial studies the side effects and best dose of MEK inhibitor MEK162 when given together with leucovorin calcium, fluorouracil, and oxaliplatin in treating patients with advanced metastatic colorectal cancer. MEK inhibitor MEK162 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving MEK inhibitor MEK162 with leucovorin calcium, fluorouracil, and oxaliplatin may kill more tumor cells.

DISEASE(S): Stage Ivb Colon Cancer,Recurrent Colon Cancer,Rectal Neoplasms,Stage Iva Rectal Cancer,Stage Ivb Rectal Cancer,Recurrent Rectal Cancer,Stage Iva Colon Cancer,Colonic Neoplasms

PROVIDER: 2159182 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2182409 | ecrin-mdr-crc
2020-01-28 | GSE138912 | GEO
2015-12-31 | GSE69657 | GEO
| 2091141 | ecrin-mdr-crc
| 2020833 | ecrin-mdr-crc
| 2097926 | ecrin-mdr-crc
| 2092221 | ecrin-mdr-crc
| 2255700 | ecrin-mdr-crc
| 2174020 | ecrin-mdr-crc
2010-06-01 | GSE16718 | GEO